SCHEMBL5283492

SCHEMBL5283492

O=C(Cn1ccc2ccccc21)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
CDK4 P11802 4/20 0.45
CCND1 P24385 4/20 0.45
NTSR1 P30989 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29827118 0.80 KMT2A (0.65) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL5336099 0.80 KMT2A (0.65) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL30379991 0.78 KMT2A (0.61) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL3864912 0.78 KMT2A (0.61) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL30229742 0.77 KMT2A (0.59) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL3597779 0.77 KMT2A (0.59) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL5279682 0.75 POLB (0.50) KMT2ALMNACYP1A2NPC1RAB9A
SCHEMBL9701534 0.75 KMT2A (0.71) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL30074152 0.75 KMT2A (0.71) KMT2AMAPK1LMNACDK4CCND1
SCHEMBL29084723 0.74 KMT2A (0.59) KMT2AMAPK1LMNACDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KMT2A 4422/4885MAPK1 3183/4885LMNA 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.